Home › Non-Small Cell Lung Cancer › Oregon › Eugene
Non-Small Cell Lung Cancer clinical trials in Eugene, OR
13 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Eugene (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
RecruitingPhase 3
- Oncology Associates Of Oregon, Pc, Eugene
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RecruitingPhase 3
- Oncology Associates of Oregon PC, Eugene
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RecruitingPhase 3
- Oncology Associates of Oregon, P.C., Eugene
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RecruitingPhase 1/2
- Oncology Associates of Oregon, P.C., Eugene
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute, Eugene
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RecruitingPhase 3
- Clinical Study Site, Eugene
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RecruitingPhase 2/3
- USOR - Willamette Valley Cancer Institute and Research Center - Eugene, Eugene
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- USO - Oncology Associates of Oregon, Eugene
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
RecruitingPhase 1
- USOR - Oncology Associates of Oregon, P.C, Eugene
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
RecruitingPhase 2
- Williamette Valley Cancer Institute and Research Center, Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RecruitingPhase 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
RecruitingPhase 1
- Willamette Valley Cancer Institute and Research Center, Eugene
MYLUNG Consortium Part 3: Observational Study
RecruitingObservational study
- Willamette Valley Cancer Institute and Research Center, Eugene
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY120 studies
- Arlington, VA104 studies
- Nashville, TN96 studies
- Boston, MA89 studies
- Los Angeles, CA87 studies
- St. Louis, MO71 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH55 studies
- Washington, DC54 studies
Other studies in Eugene
- Ovarian Cancer9 studies
- Endometrial Cancer8 studies
- Chronic Lymphocytic Leukemia7 studies
- Breast Cancer7 studies
- Metastatic Cancer6 studies
- Cancer (all types)6 studies
- Multiple Myeloma6 studies
- Lung Cancer5 studies
- Macular Degeneration5 studies
- Drug Use and Addiction5 studies
- Obesity4 studies
- Wet Macular Degeneration3 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.